Paroxysmal Nocturnal Hemoglobinuria (PNH)

Managing PNH Complications Webinar

Thumbnail for video Watch Now

Topic(s)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Presenter(s)
Srinivasa Reddy Sanikommu, MD
In this webinar, Dr. Srinivasa Sanikommu discusses the management of PNH and complications experienced by patients.

What is PNH? Webinar

Thumbnail for video Watch Now

Topic(s)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Presenter(s)
Srinivasa Reddy Sanikommu, MD
In this webinar, Dr. Srinivasa Sanikommu discusses the diagnosis of PNH and current treatments available to patients.

PLEDGE – Patients’ Long-term Experience on VOYDEYA (Danicopan): Gathering Evidence in the Real-World

Status
Recruiting
Study Date (Range)
-
Bone Marrow Disease(s)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Age Group
18 years and older
The IRB-approved observational Phase IV PLEDGE study is set-up to collect real-world data on adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) with symptomatic extravascular hemolysis who recently started VOYDEYATM (danicopan) as add-on treatment to ULTOMIRIS®…

Iptacopan Yields Meaningful Hemoglobin Improvements in Pretreated PNH Group

Original Publication Date
Article Source
External Web Content
Data from APPULSE-PNH may support oral iptacopan as a potentially practice-changing option in patients with paroxysmal nocturnal hemoglobinuria. "Results from APPULSE-PNH and previous trials establish oral iptacopan monotherapy as a potentially practice-changing treatment capable…
Subscribe to Paroxysmal Nocturnal Hemoglobinuria (PNH)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.